Shots:
- Following the CHMP’s recommendation for marketing authorization in Mar 2024, the company’s Omlyclo (biosimilar to Xolair) has obtained the EC’s approval for treating allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP)
- The approval was supported by the results from P-III clinical evaluation to determine the safety, efficacy & PK profile of Omlyclo vs Xolair among CSU patients for up to wk.40. Results demonstrated comparable efficacy, safety & immunogenicity
- Moreover, Omlyclo is currently under the US FDA’s review after its regulatory submission in Mar 2024
Ref: Businesswire | Image: Celltrion| Press Release
Related News:- Fresenius Reports the US FDA’s BLA Acceptance of FKS518 (Biosimilar, Denosumab)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
